|
1
|
Mu G, Xiang Q, Zhou S, Liu Z, Qi L, Jiang
J, Gong Y, Xie Q, Wang Z, Zhang H, et al: Efficacy and safety of
PCSK9 monoclonal antibodies in patients at high cardiovascular
risk: An updated systematic review and meta-analysis of 32
randomized controlled trial. Adv Ther. 37:1496–1521. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang DW, Garuti R, Tang WJ, Cohen JC and
Hobbs HH: Structural requirements for PCSK9-mediated degradation of
the low-density lipoprotein receptor. Proc Natl Acad Sci USA.
105:13045–13050. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paciullo F, Momi S and Gresele P: PCSK9 in
haemostasis and thrombosis: Possible pleiotropic effects of PCSK9
inhibitors in cardiovascular prevention. Thromb Haemost.
119:359–367. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grundy SM, Stone NJ, Bailey AL, Beam C,
Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S,
Faiella-Tommasino J, Forman DE, et al: 2018
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline
on the management of blood cholesterol: Executive summary: A report
of the American College of Cardiology/American Heart Association
Task Force on clinical practice guidelines. J Am Coll Cardiol.
73:3168–3209. 2019. View Article : Google Scholar
|
|
5
|
Henein MY, Vancheri S, Longo G and
Vancheri F: The role of inflammation in cardiovascular disease. Int
J Mol Sci. 23:129062022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hunt SC, Hopkins PN, Bulka K, McDermott
MT, Thorne TL, Wardell BB, Bowen BR, Ballinger DG, Skolnick MH,
Samuels ME, et al: Genetic localization to chromosome 1p32 of the
third locus for familial hypercholesterolemia in a Utah kindred.
Arterioscler Thromb Vasc Biol. 20:1089–1093. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abifadel M, Varret M, Rabès JP, Allard D,
Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich
D, et al: Mutations in PCSK9 cause autosomal dominant
hypercholesterolemia. Nat Genet. 34:154–156. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hummelgaard S, Vilstrup JP, Gustafsen C,
Glerup S and Weyer K: Targeting PCSK9 to tackle cardiovascular
disease. Pharmacol Ther. 249:1084802023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barale C, Bonomo K, Frascaroli C, Morotti
A, Guerrasio A, Cavalot F and Russo I: Platelet function and
activation markers in primary hypercholesterolemia treated with
anti-PCSK9 monoclonal antibody: A 12-month follow-up. Nutr Metab
Cardiovasc Dis. 30:282–291. 2020. View Article : Google Scholar
|
|
10
|
Andreadou I, Schulz R, Badimon L, Adameová
A, Kleinbongard P, Lecour S, Nikolaou PE, Falcão-Pires I, Vilahur
G, Woudberg N, et al: Hyperlipidaemia and cardioprotection: Animal
models for translational studies. Br J Pharmacol. 177:5287–5311.
2020. View Article : Google Scholar :
|
|
11
|
Guo Y, Yan B, Tai S, Zhou S and Zheng XL:
CSK9: Associated with cardiac diseases and their risk factors? Arch
Biochem Biophys. 704:1087172021. View Article : Google Scholar
|
|
12
|
Song L, Zhao X, Chen R, Li J, Zhou J, Liu
C, Zhou P, Wang Y, Chen Y, Zhao H and Yan H: Association of PCSK9
with inflammation and platelet activation markers and recurrent
car-diovascular risks in STEMI patients undergoing primary PCI with
or without diabetes. Cardiovasc Diabetol. 21:802022. View Article : Google Scholar
|
|
13
|
INC., F.M.I: PCSK9 inhibitor market
outlook from 2024 to 2034. 2023, (cited 2023 March 31st); Available
from: https://www.futuremarketinsights.com/reports/pcsk9-inhibitors-market.
|
|
14
|
Seidah NG, Awan Z, Chrétien M and Mbikay
M: PCSK9: A key modulator of cardiovascular health. Circ Res.
114:1022–1036. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garvie CW, Fraley CV, Elowe NH, Culyba EK,
Lemke CT, Hubbard BK, Kaushik VK and Daniels DS: Point mutations at
the catalytic site of PCSK9 inhibit folding, autoprocessing, and
interaction with the LDL receptor. Protein Sci. 25:2018–2027. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cunningham D, Danley DE, Geoghegan KF,
Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp
JS, Hoth LR, et al: Structural and biophysical studies of PCSK9 and
its mutants linked to familial hypercholesterolemia. Nat Struct Mol
Biol. 14:413–419. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wiciński M, Żak J, Malinowski B, Popek G
and Grześk G: PCSK9 signaling pathways and their potential
importance in clinical practice. EPMA J. 8:391–402. 2017.
View Article : Google Scholar
|
|
18
|
Yang L, Pu T, Zhang Y, Yan H, Yu H and Gao
W: The R93C variant of PCSK9 reduces the risk of premature mi in a
Chinese Han population. Front Genet. 13:8752692022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kwon HJ, Lagace TA, McNutt MC, Horton JD
and Deisenhofer J: Molecular basis for LDL receptor recognition by
PCSK9. Proc Natl Acad Sci USA. 105:1820–1825. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lo Surdo P, Bottomley MJ, Calzetta A,
Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A and
Carfí A: Mechanistic implications for LDL receptor degradation from
the PCSK9/LDLR structure at neutral pH. EMBO Rep. 12:1300–1305.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cameron J, Holla OL, Laerdahl JK, Kulseth
MA, Ranheim T, Rognes T, Berge KE and Leren TP: Characterization of
novel mutations in the catalytic domain of the PCSK9 gene. J Intern
Med. 263:420–431. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Timms KM, Wagner S, Samuels ME, Forbey K,
Goldfine H, Jammulapati S, Skolnick MH, Hopkins PN, Hunt SC and
Shattuck DM: A mutation in PCSK9 causing autosomaldominant
hypercholesterolemia in a Utah pedigree. Hum Genet. 114:349–353.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamamoto T, Lu C and Ryan R: A Two-step
binding model of PCSK9 interaction with the low density lipoprotein
receptor. J Biol Chem. 286:5464–5470. 2011. View Article : Google Scholar :
|
|
24
|
Hampton EN, Knuth MW, Li J, Harris JL,
Lesley SA and Spraggon G: The self-inhibited structure of
full-length PCSK9 at 1.9 A reveals structural homology with
resistin within the C-terminal domain. Proc Natl Acad Sci USA.
104:14604–14609. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fang WQ, Zhang Q, Peng YB, Chen M, Lin XP,
Wu JH, Cai CH, Mei YF and Jin H: Resistin level is positively
correlated with thrombotic complications in Southern Chinese
metabolic syndrome patients. J Endocrinol Invest. 34:e36–e42. 2011.
View Article : Google Scholar
|
|
26
|
Jamaluddin MS, Weakley SM, Yao Q and Chen
C: Resistin: Functional roles and therapeutic considerations for
cardiovascular disease. Br J Pharmacol. 165:622–632. 2012.
View Article : Google Scholar :
|
|
27
|
Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D
and Park SW: Sterol-dependent regulation of proprotein Convertase
Subtilisin/Kexin type 9 expression by sterol-regulatory element
binding protein-2. J Lipid Res. 49:399–409. 2008. View Article : Google Scholar
|
|
28
|
Costet P, Cariou B, Lambert G, Lalanne F,
Lardeux B, Jarnoux AL, Grefhorst A, Staels B and Krempf M: Hepatic
PCSK9 expression is regulated by nutritional status via insulin and
sterol regulatory element-binding protein 1c. J Biol Chem.
281:6211–6218. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li H, Dong B, Park SW, Lee HS, Chen W and
Liu J: Hepatocyte nuclear factor 1alpha plays a critical role in
PCSK9 gene transcription and regulation by the natural
hypocholesterolemic compound berberine. J Biol Chem.
284:28885–28895. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Raal F, Panz V, Immelman A and Pilcher G:
Elevated PCSK9 levels in untreated patients with heterozygous or
homozygous familial hypercholesterolemia and the response to
high-dose statin therapy. J Am Heart Assoc. 2:e0000282013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang L, McCabe T, Condra JH, Ni YG,
Peterson LB, Wang W, Strack AM, Wang F, Pandit S, Hammond H, et al:
An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin
and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci.
8:310–327. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dong B, Singh AB, Shende VR and Liu J:
Hepatic HNF1 transcription factors control the induction of PCSK9
mediated by rosuvastatin in normolipidemic hamsters. Int J Mol Med.
39:749–756. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Robinson JG, Farnier M, Krempf M, Bergeron
J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M,
et al: Efficacy and safety of alirocumab in reducing lipids and
cardiovascular events. N Engl J Med. 372:1489–1499. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sabatine MS, Giugliano RP, Keech AC,
Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T,
Wasserman SM, et al: Evolocumab and clinical outcomes in patients
with cardiovascular disease. N Engl J Med. 376:1713–1722. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ray KK, Wright RS, Kallend D, Koenig W,
Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ,
et al: Two phase 3 trials of inclisiran in patients with elevated
LDL cholesterol. N Engl J Med. 382:1507–1519. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Björkegren JLM and Lusis AJ:
Atherosclerosis: Recent developments. Cell. 185:1630–1645. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Santos RD, Gidding SS, Hegele RA, Cuchel
MA, Barter PJ, Watts GF, Baum SJ, Catapano AL, Chapman MJ, Defesche
JC, et al: Defining severe familial hypercholesterolaemia and the
implications for clinical management: A consensus statement from
the international atherosclerosis society severe familial
hypercholesterolemia panel. Lancet Diabetes Endocrinol. 4:850–861.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Raal F, Fourie N, Scott R, Blom D, De
Vries Basson M, Kayikcioglu M, Caldwell K, Kallend D and Stein E;
LIBerate-HeFH Investigators: Long-term efficacy and safety of
lerodalcibep in heterozygous familial hypercholesterolaemia: The
LIBerate-HeFH trial. Eur Heart J. 44:4272–4280. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Agarwala A, Asim R and Ballantyne CM: Oral
PCSK9 inhibitors. Curr Atheroscler Rep. Mar 27–2024. View Article : Google Scholar : Epub ahead of
print. PubMed/NCBI
|
|
40
|
Gallego-Colon E, Daum A and Yosefy C:
Statins and PCSK9 inhibitors: A new lipid-lowering therapy. Eur J
Pharmacol. 878:1731142020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Baumann S, Kettel L, Stach K, Özdemir GH,
Renker M, Tesche C, Becher T, Hetjens S, Schoepf UJ, Akin I, et al:
Serial changes in coronary plaque formation using CT angiography in
patients undergoing PCSK9-Inhibitor therapy with 1-year Follow-up.
J Thorac Imaging. 37:285–291. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ota H, Omori H, Kawasaki M, Hirakawa A and
Matsuo H: Clinical impact of PCSK9 inhibitor on stabilization and
regression of lipid-rich coronary plaques: A near-infrared
spectroscopy study. Eur Heart J Cardiovasc Imaging. 23:217–228.
2022. View Article : Google Scholar
|
|
43
|
Nishikido T: Clinical potential of
inclisiran for patients with a high risk of atherosclerotic
cardiovascular disease. Cardiovasc Diabetol. 22:202023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cammisotto V, Baratta F, Simeone PG,
Barale C, Lupia E, Galardo G, Santilli F, Russo I and Pignatelli P:
Proprotein convertase subtilisin Kexin type 9 (PCSK9) beyond
lipids: The role in oxidative stress and thrombosis. Antioxidants
(Basel). 11:5692022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Momtazi-Borojeni AA, Sabouri-Rad S, Gotto
AM, Pirro M, Banach M, Awan Z, Barreto GE and Sahebkar A: PCSK9 and
inflammation: A review of experimental and clinical evidence. Eur
Heart J Cardiovasc Pharmacother. 5:237–245. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Luquero A, Badimon L and Borrell-Pages M:
PCSK9 functions in atherosclerosis are not limited to plasmatic
LDL-Cholesterol regulation. Front Cardiovasc Med. 8:6397272021.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Navarese EP, Kolodziejczak M, Winter MP,
Alimohammadi A, Lang IM, Buffon A, Lip GY and Siller-Matula JM:
Association of PCSK9 with platelet reactivity in patients with
acute coronary syndrome treated with prasugrel or ticagrelor: The
PCSK9-REACT study. Int J Cardiol. 227:644–649. 2017. View Article : Google Scholar
|
|
48
|
Marston NA, Gurmu Y, Melloni GEM, Bonaca
M, Gencer B, Sever PS, Pedersen TR, Keech AC, Roselli C, Lubitz SA,
et al: The effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin
type 9) inhibition on the risk of venous thromboembolism.
Circulation. 141:1600–1607. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zaccardi F, Kunutsor SK, Seidu S, Davies
MJ and Khunti K: Is the lower risk of venous thromboembolism with
statins related to low-density-lipoprotein reduction? A network
metaanalysis and meta-regression of randomised controlled trials.
Atherosclerosis. 271:223–231. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Petersen-Uribe Á, Kremser M, Rohlfing AK,
Castor T, Kolb K, Dicenta V, Emschermann F, Li B, Borst O, Rath D,
et al: Platelet-derived PCSK9 is associated with LDL metabolism and
modulates atherothrombotic mechanisms in coronary artery disease.
Int J Mol Sci. 22:111792021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Konarzewski M, Szolkiewicz M,
Sucajtys-Szulc E, Blaszak J, Lizakowski S, Swierczynski J and
Rutkowski B: Elevated circulating PCSK-9 concentration in renal
failure patients is corrected by renal replacement therapy. Am J
Nephrol. 40:157–163. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Grimm J, Peschel G, Müller M, Schacherer
D, Wiest R, Weigand K and Buechler C: Rapid decline of serum
proprotein convertase Subtilisin/Kexin 9 (PCSK9) in Non-cirrhotic
patients with chronic Hepatitis C infection receiving direct-acting
antiviral therapy. J Clin Med. 10:16212021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wong Chong E, Joncas FH, Seidah NG, Calon
F, Diorio C and Gangloff A: Circulating levels of PCSK9, ANGPTL3
and Lp(a) in stage III breast cancers. BMC Cancer. 22:10492022.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Stark K and Massberg S: Interplay between
inflammation and thrombosis in cardiovascular pathology. Nat Rev
Cardiol. 18:666–682. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Camera M, Rossetti L, Barbieri SS, Zanotti
I, Canciani B, Trabattoni D, Ruscica M, Tremoli E and Ferri N:
PCSK9 as a positive modulator of platelet activation. J Am Coll
Cardiol. 71:952–954. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Panes O, González C, Hidalgo P, Valderas
JP, Acevedo M, Contreras S, Sánchez X, Pereira J, Rigotti A and
Mezzano D: Platelet tissue factor activity and membrane cholesterol
are increased in hypercholesterolemia and normalized by
rosuvastatin, but not by atorvastatin. Atherosclerosis.
257:164–171. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Schwartz GG, Szarek M, Bittner VA, Diaz R,
Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian
G, Pordy R, et al: Lipoprotein(a) and benefit of PCSK9 inhibition
in patients with nominally controlled LDL cholesterol. J Am Coll
Cardiol. 78:421–433. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Schwartz GG, Steg PG, Szarek M, Bittner
VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, et al:
Peripheral artery disease and venous thromboembolic events after
acute coronary syndrome: Role of Lipoprotein(a) and modification by
Alirocumab: Prespecified analysis of the ODYSSEY OUTCOMES
randomized clinical trial. Circulation. 141:1608–1617. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Boffa MB: Beyond fibrinolysis: The
confounding role of Lp(a) in thrombosis. Atherosclerosis.
349:72–81. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tsimikas S, Tsironis LD and Tselepis AD:
New insights into the role of lipoprotein(a)-associated
lipoprotein-associated phospholipase A2 in atherosclerosis and
cardiovascular disease. Arterioscler Thromb Vasc Biol.
27:2094–2099. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Assinger A, Wang Y, Butler LM, Hansson GK,
Yan ZQ, Söderberg-Nauclér C and Ketelhuth DF: Apolipoprotein B100
danger-associated signal 1 (ApoBDS-1) triggers platelet activation
and boosts platelet-leukocyte proinflammatory responses. Thromb
Haemost. 112:332–341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hagström E, Steg PG, Szarek M, Bhatt DL,
Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema
JW, et al: Apolipoprotein B, residual cardiovascular risk after
acute coronary syndrome, and effects of alirocumab. Circulation.
146:657–672. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Silverman MG, Ference BA, Im K, Wiviott
SD, Giugliano RP, Grundy SM, Braunwald E and Sabatine MS:
Association between lowering LDL-C and cardiovascular risk
reduction among different therapeutic interventions: A systematic
review and Meta-analysis. JAMA. 316:1289–1297. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Podrez EA, Byzova TV, Febbraio M, Salomon
RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR,
et al: Platelet CD36 links hyperlipidemia, oxidant stress and a
prothrombotic phenotype. Nat Med. 13:1086–1095. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Magwenzi S, Woodward C, Wraith KS, Aburima
A, Raslan Z, Jones H, McNeil C, Wheatcroft S, Yuldasheva N,
Febbriao M, et al: Oxidized LDL activates blood platelets through
CD36/NOX2-mediated inhibition of the cGMP/protein kinase G
signaling cascade. Blood. 125:2693–2703. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Qi Z, Hu L, Zhang J, Yang W, Liu X, Jia D,
Yao Z, Chang L, Pan G, Zhong H, et al: PCSK9 (Proprotein Convertase
Subtilisin/Kexin 9) enhances platelet activation, thrombosis, and
myocardial infarct expansion by binding to platelet CD36.
Circulation. 143:45–61. 2021. View Article : Google Scholar
|
|
67
|
Pignatelli P, Carnevale R, Di Santo S,
Bartimoccia S, Sanguigni V, Lenti L, Finocchi A, Mendolicchio L,
Soresina AR, Plebani A and Violi F: Inherited human gp91phox
deficiency is associated with impaired isoprostane formation and
platelet dysfunction. Arterioscler Thromb Vasc Biol. 31:423–434.
2011. View Article : Google Scholar
|
|
68
|
Pastori D, Nocella C, Farcomeni A,
Bartimoccia S, Santulli M, Vasaturo F, Carnevale R, Menichelli D,
Violi F and Pignatelli P; ATHERO-AF Study Group: Relationship of
PCSK9 and urinary thromboxane excretion to cardiovascular events in
patients with atrial fibrillation. J Am Coll Cardiol. 70:1455–1462.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Schlüter KD, Wolf A, Weber M,
Schreckenberg R and Schulz R: Oxidized low-density lipoprotein
(oxLDL) affects load-free cell shortening of cardiomyocytes in a
proprotein convertase Subtilisin/Kexin 9 (PCSK9)-dependent way.
Basic Res Cardiol. 112:632017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gurbel PA, Navarese EP and Tantry US:
Exploration of PCSK9 as a cardiovascular risk factor: Is there a
link to the platelet? J Am Coll Cardiol. 70:1463–1466. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kong N, Xu Q, Cui W, Feng X and Gao H:
PCSK9 inhibitor inclisiran for treating atherosclerosis via
regulation of endothelial cell pyroptosis. Ann Transl Med.
10:12052022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wang H and Bai X: Mechanisms of bone
remodeling disorder in hemophilia. Semin Thromb Hemost. 47:43–52.
2021. View Article : Google Scholar
|
|
73
|
Bovenschen N, Mertens K, Hu L, Havekes LM
and van Vlijmen BJ: LDL receptor cooperates with LDL
receptor-related protein in regulating plasma levels of coagulation
factor VIII in vivo. Blood. 106:906–912. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Paciullo F, Petito E, Falcinelli E,
Gresele P and Momi S: Pleiotropic effects of PCSK9-inhibition on
hemostasis: Anti-PCSK9 reduce FVIII levels by enhancing LRP1
expression. Thromb Res. 213:170–172. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Strickland DK, Au DT, Cunfer P and
Muratoglu SC: Low-density lipoprotein receptor-related protein-1:
Role in the regulation of vascular integrity. Arterioscler Thromb
Vasc Biol. 34:487–498. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Scalise V, Sanguinetti C, Neri T,
Cianchetti S, Lai M, Carnicelli V, Celi A and Pedrinelli R: PCSK9
induces tissue factor expression by activation of TLR4/NFkB
signaling. Int J Mol Sci. 22:126402021. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Peng J, Liu MM, Liu HH, Guo YL, Wu NQ,
Dong Q, Qian J, Dou KF, Zhu CG and Li JJ: Association of
circulating proprotein convertase Subtilisin/Kexin type 9
concentration, pro-thrombin time and cardiovascular outcomes: A
prospective cohort study. Thromb J. 19:902021. View Article : Google Scholar
|
|
78
|
Levine JA, Oleaga C, Eren M, Amaral AP,
Shang M, Lux E, Khan SS, Shah SJ, Omura Y, Pamir N, et al: Role of
PAI-1 in hepatic steatosis and dyslipidemia. Sci Rep. 11:4302021.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Cronjé HT, Nienaber-Rousseau C, Zandberg
L, Chikowore T, de Lange Z, van Zyl T and Pieters M: Candidate gene
analysis of the fibrinogen phenotype reveals the importance of
polygenic co-regulation. Matrix Biol. 60-61:16–26. 2017. View Article : Google Scholar
|
|
80
|
Zhang Y, Zhu CG, Xu RX, Li S, Guo YL, Sun
J and Li JJ: Relation of circulating PCSK9 concentration to
fibrinogen in patients with stable coronary artery disease. J Clin
Lipidol. 8:494–500. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Basiak M, Hachula M, Kosowski M and
Okopien B: Effect of PCSK9 inhibitors on hemostasis in patients
with isolated hypercholesterolemia. J Clin Med. 11:25422022.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Schol-Gelok S, Galema-Boers JAMH, van
Gelder T, Kruip MJHA, Roeters van Lennep JE and Versmissen J: No
effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in
patients with familial hypercholesterolemia. Biomed Pharmacother.
108:1412–1414. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Ahn JH, Tantry US, Kang MG, Park HW, Koh
JS, Bae JS, Cho SY, Kim KH, Jang JY, Park JR, et al: Residual
inflammatory risk and its association with events in east asian
patients after coronary intervention. JACC Asia. 2:323–337. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Ridker PM, Everett BM, Thuren T, MacFadyen
JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker
SD, et al: Antiinflammatory therapy with canakinumab for
atherosclerotic disease. N Engl J Med. 377:1119–1131. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Leung AKK, Xue YC, de Guzman A,
Grzelkovski G, Kong HJ, Genga KR, Russell JA, Boyd JH, Francis GA
and Walley KR: Modulation of vascular endothelial inflammatory
response by proprotein convertase Subtilisin-Kexin type 9.
Atherosclerosis. 362:29–37. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Raheem Lateef Al-Awsi G, Hadi Lafta M,
Hashim Kzar H, Samieva G, Alsaikhan F, Ahmad I, Mahmood Saleh M,
Alamin Altoum A, Aravindhan S, Fakri Mustafa Y, et al: PCSK9
pathway-noncoding RNAs crosstalk: Emerging opportunities for novel
therapeutic approaches in inflammatory atherosclerosis. Int
Immunopharmacol. 113:1093182022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Kattoor AJ, Goel A and Mehta JL: LOX-1:
Regulation, signaling and its role in atherosclerosis. Antioxidants
(Basel). 8:2182019. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Theofilis P, Sagris M, Antonopoulos AS,
Oikonomou E, Tsioufis C and Tousoulis D: Inflammatory mediators of
platelet activation: Focus on atherosclerosis and COVID-19. Int J
Mol Sci. 22:111702021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Liu ZY, Sun MX, Hua MQ, Zhang HX, Mu GY,
Zhou S, Wang Z, Xiang Q and Cui YM: New perspectives on the
induction and acceleration of immune-associated thrombosis by PF4
and VWF. Front Immunol. 14:10986652023. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Yurtseven E, Ural D, Baysal K and
Tokgözoğlu L: An update on the role of PCSK9 in atherosclerosis. J
Atheroscler Thromb. 27:909–918. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Ding Z, Liu S, Wang X, Theus S, Deng X,
Fan Y, Zhou S and Mehta JL: PCSK9 regulates expression of scavenger
receptors and ox-LDL uptake in macrophages. Cardiovasc Res.
114:1145–1153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Ricci C, Ruscica M, Camera M, Rossetti L,
Macchi C, Colciago A, Zanotti I, Lupo MG, Adorni MP, Cicero AFG, et
al: PCSK9 induces a pro-inflammatory response in macrophages. Sci
Rep. 8:22672018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Tang ZH, Peng J, Ren Z, Yang J, Li TT, Li
TH, Wang Z, Wei DH, Liu LS, Zheng XL and Jiang ZS: New role of
PCSK9 in atherosclerotic inflammation promotion involving the
TLR4/NF-κB pathway. Atherosclerosis. 262:113–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Puteri MU, Azmi NU, Kato M and Saputri FC:
PCSK9 promotes cardiovascular diseases: Recent evidence about its
association with platelet Activation-Induced myocardial infarction.
Life (Basel). 12:1902022.PubMed/NCBI
|
|
95
|
Vergallo R and Crea F: Atherosclerotic
plaque healing. N Engl J Med. 383:846–857. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Laugsand LE, Åsvold BO, Vatten LJ, Janszky
I, Platou CG, Michelsen AE, Damås JK, Aukrust P and Ueland T:
Circulating PCSK9 and risk of myocardial infarction: The HUNT study
in Norway. JACC Basic Transl Sci. 1:568–575. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Kimball AS, Obi AT, Diaz JA and Henke PK:
The emerging role of NETs in venous thrombosis and
immunothrombosis. Front Immunol. 7:2362016. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wang H, Wang Q, Wang J, Guo C, Kleiman K,
Meng H, Knight JS and Eitzman DT: Proprotein convertase
Subtilisin/Kexin type 9 (PCSK9) deficiency is protective against
venous thrombosis in mice. Sci Rep. 7:143602017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Heitzer T, Schlinzig T, Krohn K, Meinertz
T and Münzel T: Endothelial dysfunction, oxidative stress, and risk
of cardiovascular events in patients with coronary artery disease.
Circulation. 104:2673–2678. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Massberg S, Brand K, Grüner S, Page S,
Müller E, Müller I, Bergmeier W, Richter T, Lorenz M, Konrad I, et
al: A critical role of platelet adhesion in the initiation of
atherosclerotic lesion formation. J Exp Med. 196:887–896. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Di Minno A, Gentile M, Iannuzzo G,
Calcaterra I, Tripaldella M, Porro B, Cavalca V, Di Taranto MD,
Tremoli E, Fortunato G, et al: Endothelial function improvement in
patients with familial hypercholesterolemia receiving PCSK-9
inhibitors on top of maximally tolerated lipid lowering therapy.
Thromb Res. 194:229–236. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Metzner T, Leitner DR, Dimsity G, Gunzer
F, Opriessnig P, Mellitzer K, Beck A, Sourij H, Stojakovic T,
Deutschmann H, et al: Short-Term treatment with alirocumab,
flow-dependent dilatation of the brachial artery and use of
magnetic resonance diffusion tensor imaging to evaluate vascular
structure: An exploratory pilot study. Biomedicines. 10:1522022.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Itzhaki Ben Zadok O, Mager A, Leshem-Lev
D, Lev E, Kornowski R and Eisen A: The effect of proprotein
convertase Subtilisin Kexin type 9 inhibitors on circulating
endothelial progenitor cells in patients with cardiovascular
disease. Cardiovasc Drugs Ther. 36:85–92. 2022. View Article : Google Scholar
|
|
104
|
Ding Z, Liu S, Wang X, Deng X, Fan Y, Sun
C, Wang Y and Mehta JL: Hemodynamic shear stress via ROS modulates
PCSK9 expression in human vascular endothelial and smooth muscle
cells and along the mouse aorta. Antioxid Redox Signal. 22:760–771.
2015. View Article : Google Scholar :
|
|
105
|
Chatzizisis YS, Coskun AU, Jonas M,
Edelman ER, Feldman CL and Stone PH: Role of endothelial shear
stress in the natural history of coronary atherosclerosis and
vascular remodeling: Molecular, cellular, and vascular behavior. J
Am Coll Cardiol. 49:2379–2393. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Huang HC, Hsu SJ, Chang CC, Chuang CL, Hou
MC and Lee FY: Effects of PCSK-9 Inhibition by alirocumab
treatments on biliary cirrhotic rats. Int J Mol Sci. 23:73782022.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wu CY, Tang ZH, Jiang L, Li XF, Jiang ZS
and Liu LS: PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL
via Bcl/Bax-caspase9-caspase3 pathway. Mol Cell Biochem.
359:347–358. 2012. View Article : Google Scholar
|
|
108
|
Li J, Liang X, Wang Y, Xu Z and Li G:
Investigation of highly expressed PCSK9 in atherosclerotic plaques
and ox-LDL-induced En-Dothelial cell apoptosis. Mol Med Rep.
16:1817–1825. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Guo Y, Tang Z, Yan B, Yin H, Tai S, Peng
J, Cui Y, Gui Y, Belke D, Zhou S and Zheng XL: PCSK9 (Proprotein
Convertase Subtilisin/Kexin Type 9) triggers vascular smooth muscle
cell senescence and apoptosis: Implication of its direct role in
degenerative vascular disease. Arterioscler Thromb Vasc Biol.
42:67–86. 2022. View Article : Google Scholar
|
|
110
|
O'Leary JG, Greenberg CS, Patton HM and
Caldwell SH: AGA clinical practice update: Coagulation in
cirrhosis. Gastroenterology. 157:34–43.e1. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Subhani M, Sheth A, Ahmed J, Wijayasiri P,
Gardezi SA, Enki D, Morling JR, Aithal GP, Ryder SD and Aravinthan
AD: Incidence and prevalence of venous thromboembolism in chronic
liver disease: A Sys-Tematic review and meta-analysis. Thromb Res.
215:19–29. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Pant A, Kopec AK and Luyendyk JP: Role of
the blood coagulation cascade in hepatic fibrosis. Am J Physiol
Gastrointest Liver Physiol. 315:G171–G176. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Roberts LN, Patel RK and Arya R:
Haemostasis and thrombosis in liver disease. Br J Haematol.
148:507–521. 2010. View Article : Google Scholar
|
|
114
|
Northup PG, Garcia-Pagan JC, Garcia-Tsao
G, Intagliata NM, Superina RA, Roberts LN, Lisman T and Valla DC:
Vascular liver disorders, portal vein thrombosis, and procedural
bleeding in patients with liver disease: 2020 practice guidance by
the American association for the study of liver diseases.
Hepatology. 73:366–413. 2021. View Article : Google Scholar
|
|
115
|
Leebeek FW and Rijken DC: The fibrinolytic
status in liver diseases. Semin Thromb Hemost. 41:474–480. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Feder S, Wiest R, Weiss TS, Aslanidis C,
Schacherer D, Krautbauer S, Liebisch G and Buechler C: Proprotein
convertase Subtilisin/Kexin type 9 (PCSK9) levels are not
associated with severity of liver disease and are inversely related
to cholesterol in a cohort of thirty eight patients with liver
cirrhosis. Lipids Health Dis. 20:62021. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Grewal T and Buechler C: Emerging insights
on the diverse roles of proprotein convertase Subtilisin/Kexin type
9 (PCSK9) in chronic liver diseases: Cholesterol metabolism and
beyond. Int J Mol Sci. 23:10702022. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Schlegel V, Treuner-Kaueroff T, Seehofer
D, Berg T, Becker S, Ceglarek U, Thiery J and Kaiser T: Low PCSK9
levels are correlated with mortality in patients with end-stage
liver disease. PLoS One. 12:e01815402017. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Demers A, Samami S, Lauzier B, Des Rosiers
C, Ngo Sock ET, Ong H and Mayer G: PCSK9 induces CD36 degradation
and affects long-chain fatty acid uptake and tri-glyceride
metabolism in adipocytes and in mouse liver. Arterioscler Thromb
Vasc Biol. 35:2517–2525. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Canuel M, Sun X, Asselin MC, Paramithiotis
E, Prat A and Seidah NG: Proprotein convertase Subtilisin/Kexin
type 9 (PCSK9) can mediate degradation of the low-density
lipoprotein receptor-related protein 1 (LRP-1). PLoS One.
8:e641452013. View Article : Google Scholar
|
|
121
|
Zhang C, Shi X, Su Z, Hu C, Mu X, Pan J,
Li M, Teng F, Ling T, Zhao T, et al: CD36 deficiency ameliorates
drug-induced acute liver injury in mice. Mol Med. 27:572021.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Rada P, González-Rodríguez Á,
García-Monzón C and Valverde ÁM: Understanding lipotoxicity in
NAFLD pathogenesis: Is CD36 a key driver? Cell Death Dis.
11:8022020. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Kheirkhah A, Lamina C, Kollerits B,
Schachtl-Riess JF, Schultheiss UT, Forer L, Sekula P, Kotsis F,
Eckardt KU and Kronenberg F; GCKD Investigators: PCSK9 and
cardiovascular disease in individuals with moderately decreased
kidney function. Clin J Am Soc Nephrol. 17:809–818. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Pavlakou P, Liberopoulos E, Dounousi E and
Elisaf M: PCSK9 in chronic kidney disease. Int Urol Nephrol.
49:1015–1024. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Elewa U, Fernández-Fernández B,
Mahillo-Fernández I, Martin-Cleary C, Sanz AB, Sanchez-Niño MD and
Ortiz A: PCSK9 in diabetic kidney disease. Eur J Clin Invest.
46:779–786. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Artunc F: Kidney-derived PCSK9-a new
driver of hyperlipidemia in nephrotic syndrome? Kidney Int.
98:1393–1395. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Lutz J, Menke J, Sollinger D, Schinzel H
and Thürmel K: Haemostasis in chronic kidney disease. Nephrol Dial
Transplant. 29:29–40. 2014. View Article : Google Scholar
|
|
128
|
Lupo MG, Bressan A, Donato M, Canzano P,
Camera M, Poggio P, Greco MF, Garofalo M, De Martin S, Panighel G,
et al: PCSK9 promotes arterial medial calcification.
Atherosclerosis. 346:86–97. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Yang W, Zou B, Hou Y, Yan W, Chen T and Qu
S: Extracellular vesicles in vascular calcification. Clin Chim
Acta. 499:118–122. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Jinnouchi H, Sato Y, Sakamoto A,
Cornelissen A, Mori M, Kawakami R, Gadhoke NV, Kolodgie FD, Virmani
R and Finn AV: Calcium deposition within coronary atherosclerotic
lesion: Implications for plaque stability. Atherosclerosis.
306:85–95. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Ahamad S, Mathew S, Khan WA and Mohanan K:
Development of small-molecule PCSK9 inhibitors for the treatment of
hypercholesterolemia. Drug Discov Today. 27:1332–1349. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
de Ferranti SD, de Boer IH, Fonseca V, Fox
CS, Golden SH, Lavie CJ, Magge SN, Marx N, McGuire DK, Orchard TJ,
et al: Type 1 diabetes mellitus and cardiovascular disease: A
scientific statement from the American Heart Association and
American Diabetes Association. Circulation. 130:1110–1130. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Feingold KR: Dyslipidemia in diabetes.
2020 Aug 10. Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder
WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, et al:
Endotext (Internet) South Dartmouth (MA): MDText.com, Inc.;
2000
|
|
134
|
Morel O, Jesel L, Abbas M and Morel N:
Prothrombotic changes in diabetes mellitus. Semin Thromb Hemost.
39:477–488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Arnett DK, Blumenthal RS, Albert MA,
Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A,
Lloyd-Jones D, McEvoy JW, et al: 2019 ACC/AHA guideline on the
primary prevention of cardiovascular disease: Executive summary: A
report of the American college of Cardiology/American heart
association task force on clinical practice guidelines.
Circulation. 140:e563–e595. 2019.PubMed/NCBI
|
|
136
|
Kaur R, Kaur M and Singh J: Endothelial
dysfunction and platelet hyperactivity in type 2 diabetes mellitus:
Molecular insights and therapeutic strategies. Cardiovasc Diabetol.
17:1212018. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Dregan A, Charlton J, Chowienczyk P and
Gulliford MC: Chronic inflammatory disorders and risk of type 2
diabetes mellitus, coronary heart disease, and stroke: A
population-based cohort study. Circulation. 130:837–844. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Josefs T, Barrett TJ, Brown EJ, Quezada A,
Wu X, Voisin M, Amengual J and Fisher EA: Neutrophil extracellular
traps promote macrophage inflammation and impair atherosclerosis
resolution in diabetic mice. JCI Insight. 5:e1347962020. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Bryk-Wiązania AH and Undas A:
Hypofibrinolysis in type 2 diabetes and its clinical implications:
From mechanisms to pharmacological modulation. Cardiovasc Diabetol.
20:1912021. View Article : Google Scholar
|
|
140
|
Wu Y, Shi J, Su Q, Yang Z and Qin L:
Correlation between circulating PCSK9 levels and gestational
diabetes mellitus in a Chinese population. Front Endocrinol
(Lausanne). 13:8267572022. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Saitoski K, Ryaboshapkina M, Hamza GM,
Jarnuczak AF, Berthault C, Carlotti F, Armanet M, Sengupta K,
Underwood CR, Andersson S, et al: Proprotein convertase PCSK9
affects expression of key surface proteins in human pancreatic beta
cells via intracellular and extracellular regulatory circuits. J
Biol Chem. 298:1020962022. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Da Dalt L, Ruscica M, Bonacina F,
Balzarotti G, Dhyani A, Di Cairano E, Baragetti A, Arnaboldi L, De
Metrio S, Pellegatta F, et al: PCSK9 deficiency reduces insulin
secretion and promotes glucose intolerance: The role of the
low-density lipoprotein receptor. Eur Heart J. 40:357–368. 2019.
View Article : Google Scholar
|
|
143
|
Tchéoubi SER, Akpovi CD, Coppée F,
Declèves AE, Laurent S, Agbangla C and Burtea C: Molecular and
cellular biology of PCSK9: Impact on glucose homeostasis. J Drug
Target. 30:948–960. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Goldman A, Raschi E, Cukierman-Yaffe T,
Dankner R, Shouval R, Shechter M, Ben-Zvi I, Gerstein HC and Maor
E: Hyperglycaemic disorders associated with PCSK9 inhibitors: A
real-world, pharmacovigilance study. Eur J Prev Cardiol.
29:1334–1342. 2022. View Article : Google Scholar
|
|
145
|
Marouf BH, Iqbal Z, Mohamad JB, Bashir B,
Schofield J, Syed A, Kilpatrick ES, Stefanutti C and Soran H:
Efficacy and Safety of PCSK9 monoclonal antibodies in patients with
diabetes. Clin Ther. 44:331–348. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Furuhashi M, Sakuma I, Morimoto T,
Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M,
Nomiyama T, Arasaki O, et al: Differential effects of DPP-4
inhibitors, anagliptin and sitagliptin, on PCSK9 levels in patients
with type 2 diabetes mellitus who are receiving statin therapy. J
Atheroscler Thromb. 29:24–37. 2022. View Article : Google Scholar :
|
|
147
|
Khorana AA, Francis CW, Culakova E,
Kuderer NM and Lyman GH: Thromboembolism is a leading cause of
death in cancer patients receiving outpatient chemotherapy. J
Thromb Haemost. 5:632–634. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Kim AS, Khorana AA and McCrae KR:
Mechanisms and biomarkers of cancer-associated thrombosis. Transl
Res. 225:33–53. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Wolach O and Martinod K: Casting a NET on
cancer: The multiple roles for neutrophil extracellular traps in
cancer. Curr Opin Hematol. 29:53–62. 2022. View Article : Google Scholar
|
|
150
|
Leal AC, Mizurini DM, Gomes T, Rochael NC,
Saraiva EM, Dias MS, Werneck CC, Sielski MS, Vicente CP and
Monteiro RQ: Tumor-derived exosomes induce the formation of
neutrophil extracellular traps: Implications for the establishment
of cancer-associated thrombosis. Sci Reps. 7:64382017. View Article : Google Scholar
|
|
151
|
Li JC, Zou XM, Yang SF, Jin JQ, Zhu L, Li
CJ, Yang H, Zhang AG, Zhao TQ and Chen CY: Neutrophil extracellular
traps participate in the development of cancer-associated
thrombosis in patients with gastric cancer. World J Gastroenterol.
28:3132–3149. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Fernandes CJ, Morinaga LTK, Alves JL Jr,
Castro MA, Calderaro D, Jardim CVP and Souza R: Cancer-associated
thrombosis: The when, how and why. Eur Respir Rev. 28:1801192019.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Taxbro K, Hammarskjöld F, Thelin B, Lewin
F, Hagman H, Hanberger H and Berg S: Clinical impact of
peripherally inserted central catheters vs implanted port catheters
in patients with cancer: An open-label, randomised, two-centre
trial. Br J Anaesth. 122:734–741. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Falanga A, Russo L, Milesi V and Vignoli
A: Mechanisms and risk factors of thrombosis in cancer. Crit Rev
Oncol Hematol. 118:79–83. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Cai YJ, Li PH, Wang XA, Xu YM, Yang S,
Tang YN, Zhu Z, Yang XY, He JY, Luo H, et al: Epinephelus coioides
PCSK9 affect the infection of SGIV by regulating the innate immune
response. Fish Shellfish Immunol. 126:113–121. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Pirro M, Bianconi V, Francisci D,
Schiaroli E, Bagaglia F, Sahebkar A and Baldelli F: Hepatitis C
virus and proprotein convertase Subtilisin/Kexin type 9: A
detrimental interaction to increase viral infectivity and disrupt
lipid metabolism. J Cell Mol Med. 21:3150–3161. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Paciullo F, Fallarino F, Bianconi V,
Mannarino MR, Sahebkar A and Pirro M: PCSK9 at the crossroad of
cholesterol metabolism and immune function during infections. J
Cell Physiol. 232:2330–2338. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Yuan Y, Wu W, Sun S, Zhang Y and Chen Z:
PCSK9: A potential therapeutic target for sepsis. J Immunol Res.
2020:26876922020. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Barale C, Melchionda E, Morotti A and
Russo I: PCSK9 biology and its role in atherothrombosis. Int J Mol
Sci. 22:58802021. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Zou Y, Chen Z, Zhang X, Yu J, Xu H, Cui J,
Li Y, Niu Y, Zhou C, Xia J and Wu J: Targeting PCSK9 ameliorates
graft vascular disease in mice by inhibiting NLRP3 inflam-masome
activation in vascular smooth muscle cells. Front Immunol.
13:8947892022. View Article : Google Scholar
|
|
161
|
Sammour Y, Dezorzi C, Austin BA, Borkon
AM, Everley MP, Fendler TJ, Khumri TM, Lawhorn SL, Nassif ME,
Vodnala D, et al: PCSK9 inhibitors in heart transplant patients:
Safety, efficacy, and angiographic correlates. J Card Fail.
27:812–815. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Jennings DL, Sultan L, Mingov J, Choe J,
Latif F, Restaino S, Clerkin K, Habal MV, Colombo PC, Yuzefpulskaya
M, et al: PCSK9 inhibitors safely and effectively lower LDL after
heart transplantation: A systematic review and meta-analysis. Heart
Fail Rev. 28:149–156. 2023. View Article : Google Scholar
|
|
163
|
Ortona S, Barisione C, Ferrari PF, Palombo
D and Pratesi G: PCSK9 and other metabolic targets to counteract
ischemia/reperfusion injury in acute myocardial infarction and
visceral vascular surgery. J Clin Med. 11:36382022. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Huang G, Lu X, Zhou H, Li R, Huang Q,
Xiong X, Luo Z and Li W: PCSK9 inhibition protects against
myocardial ischemia-reperfusion injury via suppressing autophagy.
Microvasc Res. 142:1043712022. View Article : Google Scholar : PubMed/NCBI
|
